Cargando…

Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer

The role of histone deacetylases (HDACs) in lung cancer has been extensively studied. Inhibition of HDAC activities have been used as a new cancer treatment strategy. To date, many HDAC inhibitors have been shown to induce apoptosis and inhibit tumorigenesis. Chidamide (CS055) is a new member of HDA...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Na, Sun, Pan, Jin, Haizhen, Yang, Yuqin, Zhao, Qingya, Zhou, Lin, Guo, Lili, Yang, Xiaohua, Lu, Liming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365669/
https://www.ncbi.nlm.nih.gov/pubmed/32701251
http://dx.doi.org/10.1097/CAD.0000000000000935
_version_ 1783560080580411392
author Zhang, Na
Sun, Pan
Jin, Haizhen
Yang, Yuqin
Zhao, Qingya
Zhou, Lin
Guo, Lili
Yang, Xiaohua
Lu, Liming
author_facet Zhang, Na
Sun, Pan
Jin, Haizhen
Yang, Yuqin
Zhao, Qingya
Zhou, Lin
Guo, Lili
Yang, Xiaohua
Lu, Liming
author_sort Zhang, Na
collection PubMed
description The role of histone deacetylases (HDACs) in lung cancer has been extensively studied. Inhibition of HDAC activities have been used as a new cancer treatment strategy. To date, many HDAC inhibitors have been shown to induce apoptosis and inhibit tumorigenesis. Chidamide (CS055) is a new member of HDAC inhibitors. In China, Chidamide has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma. However, the efficacy of Chidamide in non-small cell lung cancer remains unclear. In this study, we used lung cancer primary cells and investigated the effects of Chidamide combined with paclitaxel on lung cancer. We found that Chidamide combined with paclitaxel effectively inhibited the expression and activity of HDAC in primary lung cancer cells, induced their apoptosis and blocked cell cycle. Chidamide combined with paclitaxel may therefore provide a new promising therapeutic treatment for lung cancer.
format Online
Article
Text
id pubmed-7365669
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-73656692020-08-05 Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer Zhang, Na Sun, Pan Jin, Haizhen Yang, Yuqin Zhao, Qingya Zhou, Lin Guo, Lili Yang, Xiaohua Lu, Liming Anticancer Drugs Preclinical Reports The role of histone deacetylases (HDACs) in lung cancer has been extensively studied. Inhibition of HDAC activities have been used as a new cancer treatment strategy. To date, many HDAC inhibitors have been shown to induce apoptosis and inhibit tumorigenesis. Chidamide (CS055) is a new member of HDAC inhibitors. In China, Chidamide has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma. However, the efficacy of Chidamide in non-small cell lung cancer remains unclear. In this study, we used lung cancer primary cells and investigated the effects of Chidamide combined with paclitaxel on lung cancer. We found that Chidamide combined with paclitaxel effectively inhibited the expression and activity of HDAC in primary lung cancer cells, induced their apoptosis and blocked cell cycle. Chidamide combined with paclitaxel may therefore provide a new promising therapeutic treatment for lung cancer. Lippincott Williams & Wilkins 2020-04-16 2020-08 /pmc/articles/PMC7365669/ /pubmed/32701251 http://dx.doi.org/10.1097/CAD.0000000000000935 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CC-BY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Preclinical Reports
Zhang, Na
Sun, Pan
Jin, Haizhen
Yang, Yuqin
Zhao, Qingya
Zhou, Lin
Guo, Lili
Yang, Xiaohua
Lu, Liming
Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer
title Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer
title_full Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer
title_fullStr Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer
title_full_unstemmed Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer
title_short Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer
title_sort chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer
topic Preclinical Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365669/
https://www.ncbi.nlm.nih.gov/pubmed/32701251
http://dx.doi.org/10.1097/CAD.0000000000000935
work_keys_str_mv AT zhangna chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer
AT sunpan chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer
AT jinhaizhen chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer
AT yangyuqin chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer
AT zhaoqingya chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer
AT zhoulin chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer
AT guolili chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer
AT yangxiaohua chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer
AT luliming chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer